This year, i2i launched the third edition of the IP2 Scale Out Program, aimed at helping promising Taiwanese startups break into the U.S. market.
On August 16th, i2i facilitated a meeting between Dr. KuoChong Lin, founder of the global biopharmaceutical innovator PharmaEssentia, and Chia-Ying Wu, Deputy Director General of the Small and Medium Enterprise and Startup Administration, MOEA. The discussion focused on potential strategies to support and promote the acceleration program, positioning Taiwan's startups for success in the U.S. East Coast and forging key partnerships.
Back in June, Gary Gong, Chairman of i2i, invited Deputy Director General Wu to visit PharmaEssentia's Boston-based Pharmaessentia Innovation Research Center (PIRC) to meet with Dr. Lin. During the meeting, they explored how PharmaEssentia’s resources in the U.S. could be leveraged to help Taiwanese startups expand globally and strengthen Taiwan-U.S. collaboration in biotech innovation.
Dr. Lin, a seasoned entrepreneur and a proud Taiwanese, expressed his willingness to guide and support the next generation of Taiwanese entrepreneurs. He plans to collaborate with i2i to explore potential partnership opportunities to foster global market growth for Taiwanese startups. This recent exchange, facilitated by i2i in Taipei, has laid the groundwork for further cooperation.
Comments